Search results for " Vasculitis"

showing 10 items of 53 documents

Genetics and pathophysiology of granulomatosis with polyangiitis (GPA) and its main autoantigen proteinase 3.

2016

Granulomatosis with polyangiitis (GPA) is a severe autoimmune disease and one of the small vessel anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitides. Although its etiology and pathophysiology are still widely unknown, it is accepted that infections, environmental factors, epigenetic modifications, and a genetic predisposition provide the basis for this systemic disorder. GPA typically evolves into two phases: an initial phase characterized by ear, nose and throat (ENT) manifestations, such as chronic sinusitis and otitis, ulceration of the oral cavity and pharynx, as well as pulmonary nodules and a severe generalized phase, defined by the occurrence of rapidly progressive g…

0301 basic medicineCandidate geneMyeloblastinGenome-wide association studyAnti-Neutrophil Cytoplasmic Antibody-Associated Vasculitismacromolecular substancesBiologyAutoantigensAntibodies Antineutrophil CytoplasmicPTPN2203 medical and health sciencesMice0302 clinical medicinestomatognathic systemProteinase 3medicineGenetic predispositionRapidly progressive glomerulonephritisAnimalsHumansGenetic Predisposition to DiseaseMolecular Biology030203 arthritis & rheumatologyAutoimmune diseaseGranulomatosis with PolyangiitisCell Biologymedicine.disease030104 developmental biologyImmunologyGranulomatosis with polyangiitisGenome-Wide Association StudyMolecular and cellular probes
researchProduct

A rare association of chronic lymphocytic leukemia with c-ANCA-positive Wegener’s granulomatosis: a case report

2016

Background Wegener’s granulomatosis is a systemic vasculitis of the small- and medium-sized vessels, produced by the action of ANCA, which involves the respiratory tract, kidneys, and eyes, with a potential for lethal evolution in the first year after diagnosis. Its association with chronic lymphocytic leukemia is rarely described in the literature, and it may be difficult to diagnose and to treat this association. Case presentation We present the case of a 73-year-old Caucasian patient, a rare case in which Wegener’s granulomatosis is associated in a patient with chronic lymphocytic leukemia, who is admitted in the Infectious Disease Department for fever, diplopia, headache, purulent and h…

0301 basic medicineChemosisMalePathologymedicine.medical_specialtyChronic lymphocytic leukemiaMucous membrane of noseCase ReportAntibodies Antineutrophil Cytoplasmic03 medical and health sciences0302 clinical medicineBiopsymedicinec-ANCA positiveHumansAgedmedicine.diagnostic_testbusiness.industryGranulomatosis with PolyangiitisWegener’s granulomatosismedicine.diseasePrognosisLeukemia Lymphocytic Chronic B-Cell030104 developmental biologyOncology030220 oncology & carcinogenesisChronic lymphocytic leukemiaSurgerymedicine.symptomGranulomatosis with polyangiitisVasculitisbusinessScleritisSystemic vasculitisWorld Journal of Surgical Oncology
researchProduct

Increased ischemic stroke, acute coronary artery disease and mortality in patients with granulomatosis with polyangiitis and microscopic polyangiitis.

2018

International audience; Objective: The aim of our study was to assess major cardiovascular event incidence, predictors, and mortality in ANCA-associated vasculitis (AAV).Methods: We conducted a retrospective cohort study of all GPA or MPA, according to Chapel Hill Consensus Conference classification criteria, diagnosed between 1981 and 2015. Major cardiovascular event was defined as acute coronary artery disease, or ischemic stroke, or peripheral vascular disease requiring a revascularization procedure. We calculated the comparative morbidity/mortality figure (CMF) and we used Cox proportional hazards regression models to assess the risk of coronary artery disease, ischemic stroke associate…

0301 basic medicineMaleRiskmedicine.medical_specialtyImmunologyPopulationMicroscopic PolyangiitisCoronary Artery DiseaseAntibodies Antineutrophil CytoplasmicCoronary artery diseaseCohort Studies03 medical and health sciences0302 clinical medicine[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemIschemiaInternal medicineImmunology and AllergyMedicineHumanseducationStrokeAgedProportional Hazards ModelsRetrospective Studies030203 arthritis & rheumatologyeducation.field_of_studyIschemic strokebusiness.industryVascular diseaseIncidence (epidemiology)Mortality rateGranulomatosis with PolyangiitisRetrospective cohort studyMiddle Agedmedicine.diseaseSurvival Analysis3. Good healthStroke030104 developmental biologyAcute DiseaseCardiologyFemalebusinessGranulomatosis with polyangiitisANCA-Associated vasculitis[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyFollow-Up StudiesJournal of autoimmunity
researchProduct

Hypertrophic pachymeningitis and cerebral venous thrombosis in myeloperoxidase-ANCA associated vasculitis

2019

Hypertrophic pachymeningitis (HP) is a circumscribed inflammatory process that thickens meninges with fibrous adhesions. Among the causes of HP, vasculitis and autoimmune disease should be considered; myeloperoxidase (MPO)-antinuclear cytoplasmatic antibodies (ANCA)-positivity can be the only

0301 basic medicinePathologymedicine.medical_specialtyImages In…PrednisoloneAnti-Neutrophil Cytoplasmic Antibody-Associated VasculitisANCA-Associated Vasculitis030105 genetics & heredityneurootologyvasculitisAntibodies Antineutrophil Cytoplasmic03 medical and health sciences0302 clinical medicinemedicineHumansskin and connective tissue diseasesPeroxidaseAutoimmune diseaseneuroimagingbiologybusiness.industryHeadacheMeningesmeningitisGeneral MedicineMiddle Agedmedicine.diseaseMagnetic Resonance ImagingVenous thrombosisTreatment Outcomemedicine.anatomical_structureMyeloperoxidasebiology.proteinFemaleSettore MED/26 - NeurologiaIntracranial ThrombosisAntibodyVasculitisbusinessheadache (including migraines)MeningitisBiomarkers030217 neurology & neurosurgeryBMJ Case Reports
researchProduct

Interleukin-9 and T helper type 9 cells in rheumatic diseases

2016

Summary Interleukin (IL)-9 is a 28-30 kDa monomeric glycosylated polypeptide belonging to the IL-7/IL-9 family of proteins that bind to a composite receptor consisting of the private receptor IL-9R and the IL-2 receptor, gamma (IL-2RG), a common gamma subunit shared by the receptors of many different cytokines. The IL-9R is expressed widely and IL-9 impacts a number of effector cells, such as effector T cells, B cells, innate lymphoid cells, mast cells, polymorphonuclear cells, epithelial cells and smooth muscle cells, playing an important role in regulating inflammatory immunity. The critical role of IL-9 in promoting cellular and humoral immune responses makes it an important focus of pot…

0301 basic medicinerheumatoid arthritispsoriatic arthritisystemic sclerosisSLEReview ArticleIL-9; psoriatic arthritis; rheumatoid arthritis; SLE; systemic sclerosis; Th9 cells; vasculitis; Immunology and Allergy; ImmunologyTh9 cellsvasculitisArthritis RheumatoidInterleukin 210302 clinical medicineT-Lymphocyte SubsetsTh9 cellIL-9; SLE; Th9 cells; psoriatic arthritis; rheumatoid arthritis; systemic sclerosis; vasculitisLupus Erythematosus SystemicMedicineImmunology and AllergyIL-2 receptorpsoriatic arthritisB-LymphocytesInterleukin-17Innate lymphoid cellT-Lymphocytes Helper-InducerAcquired immune systemInterleukin 10vasculitiInterleukin 12systemic sclerosiSignal TransductionImmunologyAutoimmune Diseases03 medical and health sciencesRheumatic DiseasesAnimalsHumans030203 arthritis & rheumatologyScleroderma Systemicbusiness.industryArthritis PsoriaticInterleukin-9rheumatoid arthritiIL-9Immunity HumoralInterleukin 33Settore MED/16 - Reumatologia030104 developmental biologyCTLA-4Immunologybusiness
researchProduct

Respiratory involvement in antineutrophil cytoplasmic antibody-associated vasculitides: a retrospective study based on POLVAS registry

2021

OBJECTIVES: The study aimed to characterise the Polish population of (ANCA)-associated vasculitides (AAV) with respiratory involvement (RI), in comparison to the subgroup without lung manifestations and the other cohorts. METHODS: Retrospective analysis of the Polish population of AAV with RI was conducted, based on data from the POLVAS registry. Standard descriptive statistics, χ2 test, and Mann-Whitney U test were used to perform comparisons. RESULTS: Among 461 cases qualified to this study, there were 316 cases with RI (68.5%), 206 with granulomatosis with polyangiitis (GPA) (65.2%), 80 with eosinophilic granulomatosis with polyangiitis (EGPA) (25.3%) and 30 with microscopic polyangiitis…

ANCAImmunologyGranulomatosis with PolyangiitisMicroscopic PolyangiitisAnti-Neutrophil Cytoplasmic Antibody-Associated VasculitisAAVChurg-Strauss SyndromevasculitisAntibodies Antineutrophil Cytoplasmiclung involvementRheumatologyRecurrenceHumansImmunology and AllergyRegistriesRetrospective Studiesrespiratory involvementClinical and Experimental Rheumatology
researchProduct

Proteinase-3 mRNA expressed by glomerular epithelial cells correlates with crescent formation in Wegener's granulomatosis

2000

Proteinase-3 mRNA expressed by glomerular epithelial cells correlates with crescent formation in Wegener's granulomatosis. Background Wegener's granulomatosis (WG) is characterized by systemic vasculitis with crescentic glomerulonephritis (CGN) and circulating autoantibodies directed against neutrophil cytoplasmic antigens (ANCA). Proteinase 3 (PR-3), a neutral serine proteinase in neutrophils implicated in the growth control of myeloid cells, has been identified as the target antigen for ANCA in WG. Since the kidneys are frequently involved in WG, we studied the in situ expression of PR-3 by renal parenchymal cells. Methods We assessed the expression of PR-3 in kidney biopsies of 15 patien…

AdultMalePathologymedicine.medical_specialtyBiopsyMyeloblastinKidney GlomerulusIn situ hybridizationBiologyurologic and male genital diseasesKidneyvasculitisAntigenProteinase 3medicineRapidly progressive glomerulonephritisHumanscrescent glomerulonephritisNorthern blotRNA Messengerrapidly progressive glomerulonephritisCells CulturedAgedKidneyANCAurogenital systemSerine EndopeptidasesGranulomatosis with PolyangiitisEpithelial CellsMiddle Agedmedicine.diseasekidney parenchymal cellsmedicine.anatomical_structureKidney TubulesNephrologyImmunohistochemistryFemaleSystemic vasculitisKidney International
researchProduct

Rituximab versus azathioprine for ANCA-associated vasculitis maintenance therapy: Impact on global disability and health-related quality of life

2016

IF 2.724 (2014); International audience; OBJECTIVES: To investigate the effects on health-related quality of life (HRQOL) and functional capability of rituximab vs azathioprine for ANCA-associated vasculitis (AAV) maintenance therapy. METHODS: In a 24-month phase III randomised-controlled trial, 115 patients over time received rituximab or azathioprine for AAV maintenance therapy. Mean changes of 36-item Short-form Health Survey (SF-36) and Health Assessment Questionnaire (HAQ) scores from baseline were analysed. RESULTS: Mean improvements of HAQ scores, from baseline to month 24 were significantly better for the rituximab (0.16 points lower) than the azathioprine group (p=0.038). As demons…

AdultMale[ SDV ] Life Sciences [q-bio][SDV]Life Sciences [q-bio]Anti-Neutrophil Cytoplasmic Antibody-Associated VasculitisMiddle Aged[SDV] Life Sciences [q-bio]AzathioprineQuality of LifeHumansDisabled PersonsFemaleRituximabAged
researchProduct

Treatment and its side effects in ANCA-associated vasculitides - Study based on POLVAS registry data.

2020

Abstract Purpose The aim of this study is to present the treatment modalities and associated side effects in a Polish nation-wide ANCA-associated vasculitides (AAV) patients’ cohort. Materials and methods Retrospective analysis of patients diagnosed with AAV between 1990 and 2016, included in the POLVAS registry was performed. Standard descriptive statistic methods were used with an emphasis on the treatment modalities. Results There were 625 patients diagnosed with AAV included in this study: 417 cases of granulomatosis with polyangiitis (GPA; 66.7%), 106 cases of microscopic polyangiitis (MPA; 17.0%) and 102 cases of eosinophilic granulomatosis with polyangiitis (EGPA; 16.3%). The mean ag…

AdultMalemedicine.medical_specialtyCyclophosphamideDrug-Related Side Effects and Adverse ReactionsAzathioprineAnti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis03 medical and health sciences0302 clinical medicineMaintenance therapyInternal medicineAzathioprinemedicineHumansTreatment complications030212 general & internal medicineRegistriesAdverse effectCyclophosphamideGlucocorticoidsANCA associated vasculitisRetrospective Studiesbusiness.industryVasculitis registryGeneral MedicineMiddle Agedmedicine.diseasePrognosisSurvival RateMethotrexate030220 oncology & carcinogenesisCohortRituximabDrug Therapy CombinationFemalePolandMicroscopic polyangiitisGranulomatosis with polyangiitisbusinessRituximabVasculitis treatmentImmunosuppressive Agentsmedicine.drugFollow-Up StudiesAdvances in medical sciences
researchProduct

Use of Biologics to Treat Relapsing and/or Refractory Eosinophilic Granulomatosis With Polyangiitis: Data From a European Collaborative Study.

2021

OBJECTIVE To describe the efficacy and safety of biologics for the treatment of eosinophilic granulomatosis with polyangiitis (EGPA). METHODS A retrospective European collaborative study was conducted in patients with EGPA who received treatment with biologics for refractory and/or relapsing disease. RESULTS Among the 147 patients with EGPA included in the study, 63 received rituximab (RTX), 51 received mepolizumab (MEPO), and 33 received omalizumab (OMA). At the time of inclusion, the median Birmingham Vasculitis Activity Score (BVAS) was 8.5 (interquartile range [IQR] 5-13) in the RTX group, while the median BVAS in the OMA group was 2 (IQR 1-4.5) and the median BVAS in the MEPO group was…

AdultMalemedicine.medical_specialtyImmunologyBirmingham Vasculitis Activity ScoreOmalizumabOmalizumabChurg-Strauss SyndromeAntibodies Monoclonal Humanized03 medical and health sciences0302 clinical medicineRheumatologyInterquartile rangeRecurrenceInternal medicinemedicineImmunology and AllergyHumansImmunologic Factors030212 general & internal medicineTreatment FailureAdverse effectGlucocorticoidsAgedRetrospective Studies030203 arthritis & rheumatologyBiological Productsbusiness.industryMiddle Agedmedicine.diseaseAsthmaTreatment OutcomeRituximabFemaleVasculitisbusinessGranulomatosis with polyangiitisRituximabMepolizumabmedicine.drugArthritisrheumatology (Hoboken, N.J.)References
researchProduct